Abstract:No associations were found between PIRCHE‐II or HLA‐EMMA and outcomes, but a trend toward increased odds of de novo donor‐specific antibody formation with higher PIRCHE‐II scores was noted. However, limited outcomes preclude definitive conclusions. Background Optimizing graft survival and diminishing human leukocyte antigen (HLA) sensitization are essential for pediatric kidney transplant recipients. More precise HLA matching predicting epitope mismatches could reduce alloreactivity. We investigated the association of predicted HLA B‐ and T‐cell molecular mismatches with the formation of de novo donor‐specific antibodies, HLA antibodies, rejection, and graft survival. Methods Forty‐nine pediatric kidney transplant recipients transplanted from 2009 to 2020 were retrospectively studied. Donors and recipients were high‐resolution HLA typed, and recipients were screened for HLA antibodies posttransplant. HLA‐EMMA (HLA Epitope MisMatch Algorithm) and PIRCHE‐II (Predicted Indirectly ReCognizable HLA Epitopes) predicted the molecular mismatches. The association of molecular mismatches and the end‐points was explored with logistic regression. Results Five recipients (11%) developed de novo donor‐specific antibodies. All five had de novo donor‐specific antibodies against HLA class II, with four having HLA‐DQ antibodies. We found no associations between PIRCHE‐II or HLA‐EMMA with de novo donor‐specific antibodies, HLA sensitization, graft loss, or rejection. However, we did see a tendency towards an increased odds ratio in PIRCHE‐II predicting de novo donor‐specific antibodies formation, with an odds ratio of 1.12 (95% CI: 0.99; 1.28) on HLA class II. Conclusion While the study revealed no significant associations between the number of molecular mismatches and outcomes, a notable trend was observed – indicating a reduced risk of dnDSA formation with improved molecular match. It is important to acknowledge, however, that the modest population size and limited observed outcomes preclude us from making definitive conclusions.

A successful second renal allograft across positive B‐cell crossmatch due to IgG anti‐HLA DR5 antibody

Impact of Alloantibody Strength in Crossmatch Negative DSA Positive Kidney Transplantation

Anti-HLA Class II Antibodies Are the Most Resistant to Desensitization in Crossmatch-positive Living-donor Kidney Transplantations: A Patient Series

Heart transplantation across the antibodies against HLA and ABO

Abo-Incompatible Living Kidney Transplantation

Four-year Allograft Survival in a Highly Sensitized Combined Liver-Kidney Transplant Patient Despite Unsuccessful Anti-Hla Antibody Reduction with Rituximab, Splenectomy, and Bortezomib.

ABO‐incompatible Living Kidney Transplantation

Effect of acute humoral rejection on renal allograft survival

Issues of Immunological and Hemodynamic Monitoring Before and During Kidney Transplantation in Sensitized Heart Transplant Recipient

Antibody response against perlecan and collagen types IV and VI in chronic renal allograft rejection in the rat

Association of non-HLA antibodies against endothelial targets and donor-specific HLA antibodies with antibody-mediated rejection and graft function in pediatric kidney transplant recipients

Impact of de novo donor-specific HLA antibodies detected by Luminex solid-phase assay after transplantation in a group of 88 consecutive living-donor renal transplantations

Successful Desensitization with Imlifidase and Daratumumab in a Highly Immunized, Crossmatch Positive, Blood Group-Incompatible Living-Donor Re-Transplant Recipient with Systemic Lupus Erythematosus and Antiphospholipid Syndrome

Impact of active antibody‐mediated rejection treatment on donor‐specific antibodies in pediatric kidney transplant recipients

Deleterious effect of T‐ and B‐cell panel reactive antibodies and donor‐specific B‐cell crossmatches on cadaveric renal allograft survival

Upfront use of eculizumab to treat early acute antibody-mediated rejection after kidney allotransplantation and relevance for xenotransplantation

Association of HLA B‐ and T‐cell molecular mismatches with HLA antibodies, rejection, and graft survival in pediatric kidney transplantation

HLA topography enforces shared and convergent immunodominant B cell and antibody alloresponses in transplant recipients

HLA antigen and HLA eplet mismatches - important factors for developing donor-specific antibodies after kidney transplantation

#6440 C1Q-BINDING ANTI-HLA DONOR-SPECIFIC ANTIBODIES AND LONG-TERM KIDNEY GRAFT OUTCOMES

Low Incidence of Acute Antibody-Mediated Rejection after HLA Desensitization in Living Donor Kidney Transplant Recipients